Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors

Journal of Medicinal Chemistry

Volumn 42, Issue 1, 1999, Pages 135-152

  De Lucca, George V ^a   Liang, Jing ^a   De Lucca, Indawati ^a  

^a DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,7 DIBENZYL 2,3,4,5,6,7 HEXAHYDRO 5,6 DIHYDROXY 1,3 BIS[4 (HYDROXYMETHYL)BENZYL] 2H 1,3 DIAZEPIN 2 ONE; DIAZEPINE DERIVATIVE; MOZENAVIR; PROTEINASE INHIBITOR; PYRIMIDINONE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG POTENCY; DRUG SOLUBILITY; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; HIV PROTEASE INHIBITORS; HIV-1; INHIBITORY CONCENTRATION 50; MICE; MODELS, MOLECULAR; PYRIMIDINONES; RATS; RNA, VIRAL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033552903     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9803626     Document Type: Article

References (38)

1. For recent reviews, see: (a) Thaisrivaongs, S. HIV Protease Inhibitors. Annu. Rep. Med. Chem. 1994, 29, 133-144.
2. (b) Kempf, D. J. Design of Symmetry-Based, Peptidomimetic Inhibitors of Human Immunodeficiency Virus Protease. Methods Enzymol. 1994, 241, 334-354.
3. Vacca, J. P. Design of Tight-Binding Human Immunodeficiency Virus Type 1 Protease Inhibitors. Methods Enzymol. 1994, 241, 311-334.
4. Darke, P. L.; Huff, J. R. HIV Protease as an Inhibitor Target for the Treatment of AIDS. Adv. Pharmacol. 1995, 25, 399-454.
5. (e) Romines, K. R.; Chrusciel, R. A. 4-Hydroxypyrones and Related Templates as Nonpeptidic HIV Protease Inhibitors. Curr. Med. Chem. 1995, 2, 825-838.
6. (f) De Clercq, E. Toward Improved Anti-HIV Chemotherapy: Therapeutic Strategies for Intervention With HIV Infections. J. Med. Chem. 1995, 38, 2491-2517.
7. (g) Boehme, R. E.; Borthwick, A. D.; Wyatt, P. G. Antiviral Agents. Annu. Rep. Med. Chem. 1995, 30, 139-149.
8. (h) Chong, K. T. Recent Advances in HIV-1 Protease Inhibitors. Exp. Opin. Invest. Drugs 1996, 5, 115-124.
9. Kempf, D. J.; Sham, H. L. HIV Protease Inhibitors. Curr. Pharm. Des. 1996, 2, 225-246.
10. (j) De Lucca, G. V.; Erickson-Viitanen, S.; Lam, P. Y. S. Cyclic HIV Protease Inhibitors Capable of Displacing the Active-Site Structural Water Molecule. Drug Discovery Today 1997, 2, 6-18.
11. (k) Vacca, J. P.; Condra, J. H. Drug Discovery Today 1997, 2, 261-272.
12. (a) Pollard, R. B. Use of Proteinase Inhibitors in Clinical Practice. Pharmacotherapy 1994, 14, 21S-29S.
13. (b) Vacca, J. P.; Dorsey, B. D.; Schlief, W. A.; Levin, R. B.; McDaniel, S. L.; Darke, P L.; Zugay, J.; Quintero, J. C.; Blahy, O. M.; Roth, E.; Sardana, V. V.; Schlabach, A. J.; Graham, P. I.; Condra, J. H.; Gotlib, L.; Holloway, M. K.; Lin, J.; Chen, I.-W.; Ostovic, D.; Anderson, P. S.; Emini, E. A.; Huff, J. R. L-735,524: an Orally Bioavailable Human Immunodeficiency Virus Type 1 Protease Inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 4096-4100.
14. Wei, X.; Ghosh, S. K.; Taylor, M. E.; Johnson, V. A.; Emini, E. A.; Deutsch, P.; Lifson, J. D.; Bonhoeffer, S.; Nowak, M. A.; Hahn, B. H.; Saag, M. S.; Shaw, G. M. Viral Dynamics in Human Immunodeficiency Virus Type 1 Infection. Nature 1995, 373, 117-122.
15. Kempf, D.; Marsh, K. C.; Denissen, J. F.; McDonald, E.; Vasavanonda, S.; Flentge, C. A.; Green, B. G.; Fino, L.; Park, C. H.; Kong, X.-P.; Wideburg, N. E.; Saldivar, A.; Ruiz, L.; Kati, W. M.; Sham, H. L.; Robins, T.; Stewart, K D.; Hsu, A.; Plattner, J. J.; Leonard, J. M.; Norbeck, D. W. ABT-538 is a Potent Inhibitor of Human Immunodeficiency Virus Protease with High Oral Bioavailability in Humans. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2484-2488.
16. (e) Ho, D. D.; Neumann, A. U.; Perelson, A. S.; Chen, W.; Leonard, J. M.; Markowitz, M. Rapid Turnover of Plasma Virions and CD4 Lymphocytes in HIV-1 Infection. Nature 1995, 373, 123-126.
17. (f) Kitchen, V. S.; Skinner, C.; Ariyoshi, K.; Lane, E. A.; Duncan, I. B.; Burckhardt, J.; Burger, H. U.; Bragman, K.; Pinching, A. J.; Weber, J. N. Safety and Activity of Saquinavir in HIV Infection. Lancet 1995, 345, 952-955.
18. (a) Lam, P. Y. S.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, N. Y.; Chang, C. H.; Weber, P. C.; Jackson, D. A.; Sharpe, T. R.; Erickson-Viitanen, S. Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors. Science 1994, 263, 380-384. For a good overview of cyclic ureas, see:
19. (b) Eyermann, C. J.; Jadhav, P. K.; Hodge, C. N.; Chang, C.-H.; Rodgers, J. D.; Lam, P. Y. S. The Role of Computer-Aided and Structure-Based Design Techniques in the Discovery and Optimization of Cyclic Urea Inhibitors of HIV Protease. In Advances in Amino Acid Mimetics and Peptidomimetics; Abel, A., Ed.; JAI Press Inc.: London, 1997; Vol. 1, pp 1-40.
20. De Lucca, G. V.; Jadhav, P. K.; Waltermire, R. E.; Aungst, B. J.; Erickson-Viitanen, S.; Lam, P. Y. S. De Novo Design and Discovery of Cyclic HIV Protease Inhibitors Capable of Displacing the Active-Site Structural Water Molecule. In Integration of Pharmaceutical Discovery and Development: Case Studies; Borchardt, R. T., Freidinger, R. M., Sawyer, T., Smith, P., Eds.; Plenum Publishing Corp.: New York, 1998; Chapter 12, pp 257-284.
21. Lam, P. Y. S.; Ru, Y.; Jadhav, P. K.; Aldrich, P. E.; De Lucca, G. V.; Eyermann, C. J.; Chang, C.-H.; Emmett, G.; Holler, E. R.; Daneker, W. F.; Li, L.; Confalone, P. N.; McHugh, R. J.; Han, Q.; Markwalder, J. A.; Seitz, S. P.; Bacheler, L. T.; Rayner, M. M.; Klabe, R. M.; Shum, L.; Winslow, D. L.; Kornhauser, D. M.; Jackson, D. A.; Erickson-Viitanen, S.; Sharpe, T. R.; Hodge, C. N. Cyclic HIV Protease Inhibitors: Synthesis, Conformational Analysis, P2/P2′ Structure-Activity Relationship, and Molecular Recognition of Cyclic Ureas. J. Med. Chem. 1996, 39, 3514-3525.
22. Hodge, C. N.; Aldrich, P. E.; Bacheler, L. T.; Chang, C.-H.; Eyermann, C. J.; Garber, S.; Grubb, M.; Jackson, D. A.; Jadhav, P. K.; Korant, B.; Lam, P. Y. S.; Maurin, M. B.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Reid, C.; Sharpe, T. R.; Shum, L.; Winslow, D. L.; Erickson-Viitanen, S. Improved Cyclic Urea Inhibitors of the HIV-1 Protease: Synthesis, Potency, Resistance Profile, Human Pharmacokinetics and X-ray Crystal Structure of DMP450. Chem. Biol. 1996, 3, 301-314.
23. De Lucca, G. V.; Liang, J.; Aldrich, P. E.; Calabrese, J.; Cordova, B.; Klabe, R. M.; Rayner, M. M.; Chang, C.-H. Design, Synthesis, and Evaluation of Tetrahydro-pyrimidinones As An Example Of A General Approach to Non-peptide HIV Protease Inhibitors. J. Med. Chem. 1997, 40, 1707-1719.
24. De Lucca, G. V.; Kim, U. T.; Liang, J.; Cordova, B.; Klabe, R. M.; Garber, S.; Bacheler, L. T.; Lam, G. N.; Wright, M. R.; Logue, K. A.; Erickson-Viitanen, S.; Ko S. S.; and Trainor, G. L. Nonsymmetric P2/P2′ Cyclic Urea HIV Protease Inhibitors. Structure-Activity Relationship, Bioavailability, and Resistance Profile of Monoindazole-Substituted P2 Analogues. J. Med. Chem. 1998, 41, 2411-2423.
25. Rodgers, J. D.; Johnson, B. L.; Wang, H.; Greenburg, R. A.; Erickson-Viitanen, S.; Klabe, R. M.; Cordova, B. C.; Rayner, M. M.; Lam, G. N.; Chang, C.-H. Potent Cyclic Urea HIV Protease Inhibitors with Benzofused Heterocycles as P2/P2′ Groups. Bioorg. Med. Chem. Lett. 1996, 6, 2919-2924.
26. (a) Greenberg, S.; Moffatt, J. G. Reactions of 2-Acyloxyisobutyryl Halides with Nucleosides. I. Reactions of Model Diols and Uridine. J. Am. Chem. Soc. 1973, 95, 4016-25.
27. (b) Russell, A. F.; Greenberg, S.; Moffatt, J. G. Reactions of 2-Acyloxyisobutyryl Halides with Nucleosides. II. Reactions of Adenosine. J. Am. Chem. Soc. 1973, 95, 4025-30.
28. De Lucca, G. V. Stereospecific, Stereoselective Rearrangement of Hexahydro-1,3-diazepin-2-ones to Tetrahydropyrimidin-2-ones and Imidazolidin-2-ones. Useful for the Synthesis of HIV Protease Inhibitors. J. Org. Chem. 1998, 63, 4755-4766.
29. Sun, J.-H.; Teleha, C. A.; Yan, J.-S.; Rodgers, J. D.; Nugiel, D. A. Efficient Synthesis of 5-(Bromomethyl) and 5-(Aminomethyl)-1-THP-Indazole. J. Org. Chem. 1997, 62, 5627-5629.
30. Han, Q.; Chang, C.-H.; Li, R.; Ru, Y.; Jadhav, P. K.; Lam, P. Y. S. Cyclic HIV Protease Inhibitors: Design and Synthesis of Orally Bioavailable, Pyrazole P2/P2́ Cyclic Ureas With Improved Potency. J. Med. Chem. 1998, 41, 2019-2028.
31. Rodgers, J. D.; Johnson, B. L.; Wang, H.; Trainor, G. L.; Anderson, P. S.; Erickson-Viitanen, S.; Klabe, R. M.; Bacheler, L.; Cordova, B. C.; Chang, C.-H. Potent Cyclic Urea HIV Protease Inhibitors with 3-Aminoindazole P2/P2́ Groups. Bioorg. Med. Chem. Lett. 1998, 8, 715-720.
32. Wilkerson, W. W.; Akamike, E.; Cheatham, W. W.; Hollis, A. Y.; Collins, D.; DeLucca, I.; Lam, P. Y. S.; Ru, Y. HIV Protease Inhibitory Bis-benzamide Cyclic Ureas: A Quantitative Structure-Activity Relationship Analysis. J. Med. Chem. 1996, 39, 4299-4312.
33. De Lucca, G. V. Synthesis and Evaluation of Delta Lactams as Non-Peptide HIV Protease Inhibitors. Bioorg. Med. Chem. Lett. 1997, 7, 501-504.
34. Jadhav, P. K.; Ala, P.; Woerner, F. J.; Chang, C.-H.; Garber, S. S.; Anton, E. D.; Bacheler, L. T. Cyclic Urea Amides: HIV-1 Protease Inhibitors with Low Nanomolar Potency against both Wild-Type and Protease Inhibitor Resistant Mutants of HIV. J. Med. Chem. 1997, 40, 181-191.
35. De Lucca, G. V. Synthesis and Evaluation of Imidazolidinones as Non-Peptide HIV Protease Inhibitors. Bioorg. Med. Chem. Lett. 1997, 7, 495-500.
36. Erickson-Viitanen, S., Klabe, R. M.; Cawood, P. G.; O'Neal, P. L.; Meek, J. L. Potency and Selectivity of Inhibition of Human Immunodeficiency Virus Protease by a Small Nonpeptide Cyclic Urea, DMP323. Antimicrob. Agents Chemother. 1994, 38, 1628-1634.
37. Bacheler, L. T.; Paul, M.; Jadhav, P. K.; Otto, M.; Stone, B.; Miller, J. A. An assay for HIV RNA in Infected Cell Lysates, and Its Use for the Rapid Evaluation of Antiviral Efficacy. Antiviral Chem. Chemother. 1994, 5, 111-121.
38. Wong, Y. N.; Burcham, D. L.; Saxton, P. L.; Erickson-Viitanen, S.; Grubb, M. F.; Quon, C. Y.; Huang, S.-M. A Pharmacokinetic Evaluation of HIV Protease Inhibitors, Cyclic Ureas, in Rats and Dogs. Biopharm. Drug. Dispos. 1994, 15, 535-544.